| Biomarker ID | 1412 |
| PMID | 24740842 |
| Year | 2014 |
| Biomarker | CDON [SNP: rs3737336: CC] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: Univariate: Cohort 1: [1.75 (95% CI: 1.01–3.04))]; Cohort 1+2: [1.66 (95% CI: 1.13–2.43)]HR: Multivariate: Cohort 1: [2.03 (95% CI: 1.08–3.81)]; Cohort 2: [1.83 (95% CI: 1.03–3.22)]; Cohort 1+2: [1.91 (95% CI: 1.25–2.91)] |
| Effect on Pathways | Pathways include: Signaling events mediated by the hedgehog family, CDO in myogenesis, Hedgehog signaling pathway, Developmental biology |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | two independent cohorts composed of 320 Asian and 526 Caucasian men with pathologically organ-confined prostate cancer were selected |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: Cohort 1: p= 0.05 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.03 Cohort 2: p = 0.04 Cohort 1+2: p=0.003 |
| Method Used | MALDI-TOF |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |